Jesus Corral

Jesus Corral

UNVERIFIED PROFILE

Are you Jesus Corral?   Register this Author

Register author
Jesus Corral

Jesus Corral

Publications by authors named "Jesus Corral"

Are you Jesus Corral?   Register this Author

25Publications

1055Reads

9Profile Views

Effects of dose modifications on the safety and efficacy of dacomitinib for mutation-positive non-small-cell lung cancer.

Future Oncol 2019 Aug 17;15(24):2795-2805. Epub 2019 Jul 17.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0299DOI Listing
August 2019

Management of common adverse events related to first-line dacomitinib use in mutation-positive non-small-cell lung cancer: a pooled safety analysis.

Future Oncol 2019 May 6;15(13):1481-1491. Epub 2019 Mar 6.

State Key Laboratory of South China, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0944DOI Listing
May 2019

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.

Invest New Drugs 2019 02 9;37(1):98-108. Epub 2018 Jun 9.

Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, C/Dr. Esquerdo 46, 28009, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0614-9DOI Listing
February 2019

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

J Clin Oncol 2018 08 4;36(22):2244-2250. Epub 2018 Jun 4.

Tony S. Mok, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Xiangdong Zhou, First Affiliated Hospital of Third Military Medical University, Chongqing; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; Ki Hyeong Lee, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea; Kazuhiko Nakagawa, Kindai University Hospital, Osaka; Seiji Niho, National Cancer Center Hospital East, Kashiwa, Japan; Min Lee, SFJ Asia Pacific, Singapore; Rolf Linke, SFJ Pharmaceuticals Group, Pleasanton, CA; Rafael Rosell, Catalan Institute of Oncology, Barcelona; Jesus Corral, Hospital Universitario Virgen del Rocio, Seville, Spain; Maria Rita Migliorino, Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy; Adam Pluzanski, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Eric I. Sbar, Pfizer, Collegeville, PA; Tao Wang and Jane Liang White, Pfizer, Groton, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7994DOI Listing
August 2018

Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians.

Clin Lung Cancer 2017 03 26;18(2):e89-e97. Epub 2016 Oct 26.

Thoracic Oncology, Lungen Clinic Grosshansdorf, Member of the German Center for Lung Research, Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.10.004DOI Listing
March 2017

Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.

J Antimicrob Chemother 2014 Dec 4;69(12):3268-74. Epub 2014 Aug 4.

Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dku290DOI Listing
December 2014

Treatment for early-stage lung cancer: what next?

Lancet 2014 May 25;383(9928):1528-30. Epub 2014 Feb 25.

Instituto de Biomedicina de Sevilla-IBIS, Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(14)60002-7DOI Listing
May 2014

Sorafenib in metastatic thyroid cancer.

Endocr Relat Cancer 2012 Apr 10;19(2):209-16. Epub 2012 Apr 10.

Medical Oncology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-11-0351DOI Listing
April 2012

FGF receptor inhibitors: role in cancer therapy.

Curr Oncol Rep 2012 Apr;14(2):111-9

Drug Development Unit, Division of Cancer Therapeutics, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-012-0225-0DOI Listing
April 2012

Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer.

J Clin Oncol 2011 Mar 13;29(7):e163-5. Epub 2010 Dec 13.

Hospital Universitario Virgen del Rocío, Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.31.4641DOI Listing
March 2011

Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.

J Clin Virol 2005 Jul 12;33(3):224-9. Epub 2005 Jan 12.

Viral Pathogenesis Department, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Carretera de Majadahonda a Pozuelo, 28220 Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcv.2004.06.014DOI Listing
July 2005